Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany - Schneeweiss, Andreas; Ettl, Johannes; Lüftner, Diana (Friedrich-Alexander-Universität Erlangen-Nürnberg, 2020)
Keywords: Advanced breast cancer; Metastatic; Chemotherapy; Endocrine therapy; CDK4/6; Ribociclib; Palbociclib; Abemaciclib